Cancer Center– A Cancer Center Designated by
the National Cancer Institute

Clinical Trials in the Category "Multiple Myeloma"

Drug Intervention Trials that are Recruiting

Study Title
 Principal Investigator Disease Category
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Laura Johnston
 Myeloproliferative Disorders
Leukemia
Lymphoma
Graft vs Host Disease
Myelodysplastic Syndromes
Multiple Myeloma
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients Steven Edward Coutre
 Multiple Myeloma
Bone Diseases
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma (FIRST) Steven Edward Coutre
 Multiple Myeloma


Other Trials that are Recruiting

Study Title
 Principal Investigator Disease Category
Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Wen-Kai Weng
 Transplantation, Homologous
Transplantation, Autologous
Multiple Myeloma
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation Robert S Negrin
 Multiple Myeloma
Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation Robert S Negrin
Judith Anne Shizuru
 Leukemia, Myeloid
Lymphoma, Non-Hodgkin
Multiple Myeloma
NMDP Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation David Miklos
 Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic
Multiple Myeloma

Trials not Recruiting

Study Title
 Principal Investigator Disease Category
Mixed Chimera Allo Transplantation in Multiple Myeloma
(No longer recruiting) 		Wen-Kai Weng
 Blood Cancer
Multiple Myeloma
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
(Completed) 		Robert Lowsky
 Multiple Myeloma
Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
(Completed) 		Ronald Levy
 Multiple Myeloma
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
(No longer recruiting) 		Sally Arai
 Leukemia
Multiple Myeloma
High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
(No longer recruiting) 		Sally Arai
 Multiple Myeloma
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
(Completed) 		Steven Edward Coutre
 Leukemia
Waldenstrom Macroglobulinemia
Lymphoma, Non-Hodgkin
Multiple Myeloma
Study of Intravenously Administered SNS-032 in Patients With Advanced B-Lymphoid Malignancies
(No longer recruiting) 		Steven Edward Coutre
 Leukemia, Lymphocytic, Chronic
Multiple Myeloma
Ph 3 Open-label KOS953+Bortezomib compared to Bortezomib for First Relapse MM
(Suspended) 		Bruno Carneiro de Medeiros
 Multiple Myeloma
Phase 1/2 Study of VELCADEŽ, Dexamethasone, and RevlimidŽ Versus VELCADE, Dexamethasone, Cyclophosphamide, and Revlimid in Patients With Previously Untreated Multiple Myeloma (EVOLUTION)
(Completed) 		Bruno Carneiro de Medeiros
 Multiple Myeloma


The physicians of the Stanford Cancer Center are engaged in more than 250 clinical trials.  Contracts with some of our clinical trial sponsors prevent us from listing specific trial information on our web site. Please contact the Stanford Cancer Clinical Trials Office at 650-498-7061 for information about additional open clinical trials.

Stanford Medicine Resources:

Footer Links: